METHOD FOR THE ETIOPATHOGENETIC TREATMENT OF PARAVASAL DISORDERS OF BULBAR CONJUNCTIVA IN PATIENTS WITH COVID-19 ASSOCIATED PNEUMONIA Russian patent published in 2021 - IPC A61K31/4415 A61K31/51 A61K31/728 A61K31/519 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of paravasal disorders of the bulbar conjunctiva in patients who have had COVID-19 associated pneumonia. The method includes determining the level of homocysteine and cystatin C of blood serum in patients with COVID-19 associated pneumonia, with biomicroscopically confirmed paravasal disorders of the bulbar conjunctiva in the form of widespread or local edema, hemorrhages. When homocysteine levels in women are more than 12 mcmol/l, in men more than 15 mcmol/l and cystatin C is more than 1.12 mg/l, folic acid is prescribed orally at a dosage of 1 mg 3 times a day for 1 month, combilipen orally, 1 tablet 1 time per day for 1 month, as well as ophthalmic solution chiloparin-chest of drawers, 1 drop 3 times a day in both eyes for 1 month.

EFFECT: use of the invention makes it possible to arrest the symptoms of paravasal disorders of the bulbar conjunctiva within 1 month.

1 cl, 2 ex